What patents does Salspera, Inc. hold, and how is the intellectual property of Saltikva protected?

The assignee records for US Patent 11,576,936 ↗ (granted 2023-02-14) and US Patent 12,090,179 ↗ (granted 2024-09-17) name Salspera LLC, the predecessor of Salspera, Inc. (developer of Saltikva). The granted claims cover methods and combinations pairing a chemotherapy agent below its maximum tolerated dose with attenuated Salmonella typhimurium, and in the later patent a Salmonella that expresses human IL-2. The S-1/A No. 3 ↗ also lists pending applications in the United States, Europe and other jurisdictions, which are company-stated and which have not been independently checked. Google Patents lists an adjusted expiry of 2040-01-02 for US Patent 11,576,936, which is not a legal determination; the expiry of US Patent 12,090,179 is not reported in the sources reviewed. The intellectual property for Saltikva belongs wholly to Salspera and is not licensed from any university, and the company does not depend on any intellectual property owned by the University of Minnesota to develop, manufacture or commercialize Saltikva (S-1/A No. 3). The S-1/A separately reports a University of Minnesota license held by a subsidiary for an unrelated bacterial construct. Salspera, Inc. has not published a freedom-to-operate analysis.